On-Demand
Pain Management/Pharmacology CME
Purchase Now!
$147
Keep up-to-date on the latest in acute and chronic pain management and use of treatment options for the management of GI, infectious diseases, and respiratory conditions in this fast-paced course.
CME On-Demand Courses Include
Package 1 – Pain Management, Pharmacology & Prescribing
CME Courses by Jeremy A. Adler, DMSc, PA-C, DFAAPA
Chronic Pain Conditions – A Deeper Dive Into the Usual Suspects (Rx=0.25)
Millions of American experience chronic pain, and over 4% of the population reports having high-impact chronic pain. Chronic pain is a common complaint and has considerable comorbidities, sequelae, and costs. This session will review some of the more common chronic pain conditions, including a review of symptoms, signs, and supportive diagnostic information. Some conditions to be covered include chronic low back pain, neck pain, joint pain, and neuropathies. Attendees will enhance their confidence in diagnosis, which, with a patient-specific treatment plan, will improve treatment outcomes.
Pain Pathophysiology Part 1 – Bridging the Mechanism of
Action of Non-opioid Medications (Rx=0.25)
Without a single therapeutic option achieving complete efficacy and safety for those experiencing chronic pain, clinicians are presented with a significant diversity of pharmacologic options to consider. Treatment guidelines have consistently put forward strong recommendations to leverage the analgesic properties of non-opioid medications, but how does one decide between a calcium channel modulator, a serotonin-norepinephrine reuptake inhibitor, or a non-steroidal anti-inflammatory? Attendees of this session will explore the basic neuroanatomy and physiology of nociception, focusing on the mechanism of action of non-opioid medications. By connecting the pharmacologic site of action to a patient’s underlying pain condition, a more rational approach will occur in selecting non-opioid medications.
Pain Pathophysiology Part 2 – Bridging the Mechanism of Action
of Opioid Medications (Rx=0.25)
With the isolation of a specific opiate from opium in 1805, the foundation of modern opioid pharmaceuticals was set. Globally, opioids remain important medications, with their position secured on the World Health Organization’s list of essential medicines. Since their initial discovery, a number of opioids have been formulated. The obvious question is, “Are all opioids the same?” This session will review the underlying neuroanatomy and physiology specific to opioids. Building upon the mechanism of action of opioids, specific effects of pharmacogenetics, metabolism-based drug interactions, and opioid receptor binding actions will be uncovered. Individual opioids, especially synthetic opioids, will challenge the concept that all opioids are equivalent.
Aberrant Behaviors & Patient Monitoring (Rx=0.50)
Despite advances in non-pharmacologic treatments and non-opioid medications for patients with chronic pain, many patients have inadequately managed pain and may be appropriate candidates for opioid therapy. For these patients, careful monitoring is essential and clinical guidelines support using tools such as urine drug monitoring and prescription drug monitoring program data. Like every medical test, these tools have specificities and sensitivities that may yield results that are either consistent or inconsistent with the clinical impressions. This session will examine the various laboratory technologies of drug monitoring, including screening and definitive testing. Connections will be drawn between the laboratory results and unexpected and expected findings from individual opioids, including the impact of pharmacogenetics, drug interactions, and manufacturing impurities. Other monitoring tools, including prescription drug monitoring programs, will be discussed. Finally, attendees will have the opportunity to apply the content to a review of actual case studies of patient aberrant behaviors. Some circumstances are what they seem, and some are not.
Innovations in Interventional Pain Management
Although pharmacologic treatments remain a common component of managing pain, significant advances in interventional pain management have reached a point where patients may successfully reduce medications or may not require them at all. This session will review some of the longstanding approaches, such as epidural steroids and radiofrequency neurotomies, but also increase awareness of understanding of interventional treatment options for joint pain of the knee, hip, and shoulder as well as advances in minimally invasive pain, reliving surgical treatments within the scope of pain management. Attendees will also be introduced to the innovative advances in neuromodulation and targeted intrathecal drug delivery.
CME Courses by Shelagh Larson DNP, APRN, WHNP-BC, NCMP
The Gyn Visit: Bleeding, Cyst, and Fibroids (Rx=0.25)
In this session, we will start getting those dreaded Gyn visits out of the way. We will go in-depth into why there is heavy or no bleeding and how to test and treat it. Next, we will tackle the cyst issue that haunts every ObGyn. You will be able to understand what and why, and how to treat. Next, the fibroid fiasco will be broken down. You will be able to discuss these concerns like a champ. We will also have time to discuss some vulvar issues.
Contraceptive Update: What’s New, Out and In the Pipeline (Rx=0.50)
Contraceptive choices have widened. In the second session, we will examine not only what’s new for women, but male contraceptives will be introduced. You will understand why you would lick one over another, and I’ll even provide a “cheat sheet” for when you get home.
STI Update: CDC 2021 STI Treatment Guidelines (Rx=0.75)
Just when you memorized the old STD treatments, CDC came along and changed the name and treatment regimen. We will discuss why the name changed from STD to STI, additional STI screenings, and the modifications in treatments. We will also discuss your role in the treatment of sexual partners.
Menopause Matrix: Rising from the Hot Flash Ashes (Rx=0.50)
STIs are not the only treatment modality to get a facelift. The North American Menopause Society (NAMS) updated menopause guidelines in 2022. A point of clarification will happen during this session. You will leave this conference confident about hormone therapy and prescribing to menopausal women.
Not Tonight Honey, I Have a Headache: Sexual Dysfunction (Rx=0.50)
We will end the day with a little sex (discussion). You will appreciate the different sexual response phases and what drugs and conditions that interfere with them. You will have all the right tools to open sexual health discussions and understand “what and why” there may be a problem. Alternatives, medications, and new treatments will be examined.